External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma

Shuzo Hamamoto; Yoshihiko Tasaki; Shimpei Yamashita; Junya Furukawa; Kazutoshi Fujita; Ryotaro Tomida; Makito Miyake; Noriyuki Ito; Hideto Iwamoto; Yosuke Sugiyama; Kazumi Taguchi; Takahiro Yasui

doi:10.3389/fonc.2024.1400041

Frontiers in Oncology (Sep 2024)

External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma

Shuzo Hamamoto,
Yoshihiko Tasaki,
Shimpei Yamashita,
Junya Furukawa,
Kazutoshi Fujita,
Ryotaro Tomida,
Makito Miyake,
Noriyuki Ito,
Hideto Iwamoto,
Yosuke Sugiyama,
Kazumi Taguchi,
Takahiro Yasui

Affiliations

Shuzo Hamamoto: Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Yoshihiko Tasaki: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Shimpei Yamashita: Department of Urology, Wakayama Medical University, Wakayama, Japan
Junya Furukawa: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
Kazutoshi Fujita: Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan
Ryotaro Tomida: Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
Makito Miyake: Department of Urology, Nara Medical University, Kashihara, Japan
Noriyuki Ito: Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
Hideto Iwamoto: Division of Urology, Department of Surgery, Tottori University Faculty of Medicine Graduate School of Medicine, Tottori, Japan
Yosuke Sugiyama: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Kazumi Taguchi: Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Takahiro Yasui: Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

DOI: https://doi.org/10.3389/fonc.2024.1400041
Journal volume & issue: Vol. 14

Abstract

Read online

IntroductionPretreatment hemoglobin and neutrophil levels were previously reported to be important indicators for predicting the effectiveness of ipilimumab plus nivolumab (IPI + NIVO) therapy for renal cell carcinoma (RCC). Therefore, we aimed to validate this in a large external cohort.MethodsIn total, 172 patients with RCC who underwent IPI + NIVO treatment at a multicenter setting were divided into three groups according to their pretreatment hemoglobin and neutrophil levels (group 1: non-anemia; group 2: anemia and low-neutrophil; and group 3: anemia and high-neutrophil).ResultsGroup 1 showed better survival than groups 2 and 3 (overall survival: 52.3 vs. 21.4 vs. 9.4 months, respectively; progression-free survival: 12.1 vs. 7.0 vs. 3.4 months, respectively).DiscussionIn this large cohort, we validated our earlier observation that hemoglobin and neutrophil levels can be reliable predictors of the effectiveness of IPI + NIVO in advanced RCC. Thus, our approach may aid in selecting the optimal first-line therapy for RCC.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords